Literature DB >> 11081387

Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality.

S Chakrabarti1, A Lees, S G Jones, D W Milligan.   

Abstract

We retrospectively evaluated 75 allogeneic stem cell transplant recipients to ascertain the incidence, risk factors and outcome of infection with Clostridium difficile. Ten patients (13%) had Clostridium difficile infection at a median of 38 days (range day -6 to day +72) following the transplant. There was no difference in the duration or severity of diarrhoea in patients with Clostridium difficile infection compared to the uninfected patients and no relationship to the prior antibiotic or chemotherapy usage, age, gender, underlying disease, donor type, CMV serostatus, total body irradiation or time to engraftment. The incidence of viral infections was increased in patients infected with Clostridium difficile (7/10 vs 15/65, P = 0.005, odds ratio 7.7), but the strongest association was with GVHD >grade 2 (5/10 vs 6/65 uninfected patients, P = 0.004, odds ratio 9.8). Patients infected with Clostridium difficile also suffered a higher non-relapse mortality with 7/10 patients succumbing to either GVHD or infections, compared to 19/65 patients in the uninfected group (P = 0.02, odds ratio 5.6). Thus Clostridium difficile infections in our study had a strong association with GVHD and increased non-relapse mortality. It is possible that Clostridium difficile toxin might predispose to increased severity of GVHD leading to an adverse outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081387     DOI: 10.1038/sj.bmt.1702627

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  40 in total

1.  Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.

Authors:  Teena Chopra; Pranatharthi Chandrasekar; Hossein Salimnia; Lance K Heilbrun; Daryn Smith; George J Alangaden
Journal:  Clin Transplant       Date:  2010-10-25       Impact factor: 2.863

Review 2.  Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.

Authors:  Steven Naymagon; Leonard Naymagon; Serre-Yu Wong; Huaibin Mabel Ko; Anne Renteria; John Levine; Jean-Frederic Colombel; James Ferrara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

3.  Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yeon Joo Lee; Esther S Arguello; Robert R Jenq; Eric Littmann; Grace J Kim; Liza C Miller; Lilan Ling; Cesar Figueroa; Elizabeth Robilotti; Miguel-Angel Perales; Juliet N Barker; Sergio Giralt; Marcel R M van den Brink; Eric G Pamer; Ying Taur
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

Review 4.  Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis.

Authors:  Carolyn D Alonso; Kieren A Marr
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

5.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

6.  The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  Ying Taur; Robert R Jenq; Miguel-Angel Perales; Eric R Littmann; Sejal Morjaria; Lilan Ling; Daniel No; Asia Gobourne; Agnes Viale; Parastoo B Dahi; Doris M Ponce; Juliet N Barker; Sergio Giralt; Marcel van den Brink; Eric G Pamer
Journal:  Blood       Date:  2014-06-17       Impact factor: 22.113

7.  Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients.

Authors:  E R Dubberke; K A Reske; M A Olsen; K Bommarito; A A Cleveland; F P Silveira; M G Schuster; C A Kauffman; R K Avery; P G Pappas; T M Chiller
Journal:  Transpl Infect Dis       Date:  2018-03-06       Impact factor: 2.228

8.  Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.

Authors:  S Mani; L Rybicki; D Jagadeesh; S B Mossad
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 9.  The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Authors:  Sohn Kim; April Covington; Eric G Pamer
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

10.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.